Is EXELIXIS, INC. (EXEL) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 1.6% / 30% | 9.5% / 30% | 2.6% / 30% | 2.98% / 5% | ✓ HALAL |
| DJIM | 1.6% / 33% | 9.5% / 33% | 2.6% / 33% | 2.98% / 5% | ✓ HALAL |
| MSCI | 6.1% / 33% | 37.2% / 33% | 10.1% / 33% | 2.98% / 5% | ✗ NOT HALAL |
| S&P | 1.6% / 33% | 9.5% / 33% | 2.6% / 33% | 2.98% / 5% | ✓ HALAL |
| FTSE | 6.1% / 33% | 37.2% / 33% | 10.1% / 50% | 2.98% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 96.4% | |
| Operating Margin | 39.4% | |
| Net Margin | 33.7% | |
| Return on Equity (ROE) | 35.5% | |
| Return on Assets (ROA) | 19.3% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $884M |
| Free Cash Flow | $844M |
| Total Debt | $173M |
| Debt-to-Equity | 9.3 |
| Current Ratio | 3.6 |
| Total Assets | $2.8B |
Price & Trading
| Last Close | $42.36 |
| 50-Day MA | $42.81 |
| 200-Day MA | $41.55 |
| Avg Volume | 2.8M |
| Beta | 0.4 |
|
52-Week Range
$32.38
| |
About EXELIXIS, INC. (EXEL)
Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent oral inhibitor of kinases, including the TAM kinases, MET, and VEGF receptors; XL309, a small molecule inhibitor of USP1, a synthetic lethal target in the context of BRCA-mutated tumors; XB010, an antibody-drug conjugates (ADC) consisting of a MMAE payload conjugated to a monoclonal antibody targeting the tumor antigen 5T4; XB628, a first-in-class bispecific antibody that targets programmed cell death ligand 1and natural killer cell receptor group 2A; and XB371, a next-generation tissue factor targeting ADC with a topoisomerase inhibitor payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Catalent, Inc.; Iconic Therapeutics, Inc.; Adagene Inc.; Invenra, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as business development activities and other collaborations. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
Purification Calculator
As a halal stock with 2.98% impermissible income, you need to purify your dividends.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is EXELIXIS, INC. (EXEL) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), EXELIXIS, INC. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is EXELIXIS, INC.'s debt ratio?
EXELIXIS, INC.'s debt ratio is 1.6% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 6.1%.
Does EXELIXIS, INC. require dividend purification?
Yes, EXELIXIS, INC. has an impermissible income ratio of 2.98%, which means 2.98% of any dividends received should be donated to charity as purification. This is because a small portion of the company's revenue comes from non-Shariah-compliant sources.
What are EXELIXIS, INC.'s key financial metrics?
EXELIXIS, INC. has a market capitalization of $11.1B, trailing P/E ratio of 14.9, and revenue of $2.3B. The company maintains a gross margin of 96.4% and a net margin of 33.7%. Return on equity stands at 35.5%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.